Ignite Creation Date:
2024-05-06 @ 4:47 PM
Last Modification Date:
2024-10-26 @ 2:16 PM
Study NCT ID:
NCT05092360
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-28
First Post:
2021-10-13
Brief Title:
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer ARTISTRY-7
Sponsor:
Mural Oncology Inc
Organization:
Mural Oncology Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-10
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-05
Completion Date Type:
ESTIMATED
First Submit Date:
2021-10-13
First Submit QC Date:
October 13 2021
Study First Post Date:
2021-10-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-06-27
Last Update Post Date:
2024-06-28
Last Update Post Date Type:
ACTUAL